Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Corthotec Ltd. operates within the Biotechnology & Pharmaceuticals technology area with a very specific prosecution footprint. The company currently has 1 pending office action, which serves as the primary focus of its interaction with the USPTO. This pending matter is assigned to REGLAS, GILLIAN CHELSEA, who is designated as the busiest examiner for the portfolio. The commitment to this space is evident in the company's current filing activity.
The portfolio's current activity is limited to 1 distinct examiner and a distinct art unit, indicating a centralized examination process. Since REGLAS, GILLIAN CHELSEA is handling the busiest examiner pending action, the company's prosecution results are currently dependent on the feedback from a single individual. This concentration means that the company is not currently exposed to the varying interpretations that might arise from a larger pool of examiners or different art units. For those managing this portfolio, the singular focus in the Biotechnology & Pharmaceuticals space requires a precise response to the specific requirements of the assigned art unit.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REGLAS, GILLIAN CHELSEA | 1 | 30.2% | +41.5% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17268023 | COMPOSITION FOR IMPROVED BONE FRACTURE HEALING | REGLAS, GILLIAN CHELSEA | 46d overdue |
| Art Unit | Apps |
|---|---|
| 1632 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17268023 | COMPOSITION FOR IMPROVED BONE FRACTURE HEALING | REGLAS, GILLIAN CHELSEA | 1632 | §103 | Final Rejection | 46d overdue | Pending | Feb 11, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial